Reversibility of immune checkpoint inhibitor-induced hypothyroidism
Endocrine-Related Cancer · 2025
DOI: 10.1530/erc-25-0138 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine-Related Cancer, 2025. Verfasst von Jeongmin Seo und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Hypothyroidism, Thyroxine, Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment but can induce immune-related adverse events, most commonly hypothyroidism. The reversibility of ICI-induced hypothyroidism and the potential for discontinuing levothyroxine (LT4) treatment remain unclear. This retrospective study analyzed patients who developed hypothyroidism due to ICI treatment and were prescribed LT4 at a tertiary referral hospital from January 2016 to March 2024. Among 3,753 patients treated with ICIs, 254 (6.8%) developed hypothyroidism requiring LT4 treatment. Of the 184 patients who discontinued ICI, only 10 (5.4%) discontinued LT4 during a median follow-up of 13.2 months, while none did among those continuing ICIs. Multivariable Cox regression analysis revealed that the use of ICIs in early-stage cancer (HR 13.40, 95% CI: 1.99–90.06, P = 0.008) and TSH <20 μIU/mL before starting LT4 (HR 15.16, 95% CI: 2.17–105.85, P = 0.006) significantly increased the likelihood of discontinuing LT4. These findings suggest that while recovery from ICI-induced hypothyroidism is uncommon, patients treated for early-stage cancer and those with lower TSH levels before starting LT4 may have a greater likelihood of recovery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
- Division of Endocrinology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
- Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
- Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
ORCID-Profile: Jeongmin Seo, Min Joo Kim
Zitieren
APA
Seo, J., Kim, M. J., Kang, M., Jung, E. H., Suh, K. J., Kim, J. W., Kim, S. H., Kim, J. W., Kim, Y. J., Lee, K. W., Kim, J. H., Lee, J. S., Cho, S. W., & Moon, J. H. (2025). Reversibility of immune checkpoint inhibitor-induced hypothyroidism. Endocrine-Related Cancer. https://doi.org/10.1530/erc-25-0138
Vancouver
Seo J, Kim MJ, Kang M, Jung EH, Suh KJ, Kim JW, et al. Reversibility of immune checkpoint inhibitor-induced hypothyroidism. Endocrine-Related Cancer. 2025. doi:10.1530/erc-25-0138
BibTeX
@article{Seo2025,
author = {Seo, Jeongmin and Kim, Min Joo and Kang, Minsu and Jung, Eun Hee and Suh, Koung Jin and Kim, Ji-Won and Kim, Se Hyun and Kim, Jin Won and Kim, Yu Jung and Lee, Keun-Wook and Kim, Jee Hyun and Lee, Jong Seok and Cho, Sun Wook and Moon, Jae Hoon},
title = {Reversibility of immune checkpoint inhibitor-induced hypothyroidism},
journal = {Endocrine-Related Cancer},
year = {2025},
doi = {10.1530/erc-25-0138}
}
EUVIMED